HCW starts Harpoon Therapeutics at buy; PT $28

Harpoon Therapeutics

H.C. Wainwright launched coverage of Harpoon Therapeutics (NASDAQ:HARP) with a “buy” rating and $28 price target. The stock closed at $13.29 on Jan. 31.

Harpoon is advancing a proprietary platform of redirected T cell therapies, TriTACs, across solid tumors as well as multiple myeloma.

Key proof-of-concept data from two wholly-owned assets, HPN424, a PSMA-targeted TriTAC, and HPN536, a mesothelin-targeted TriTAC, are anticipated during the first half and second half of 2020, respectively, writes analyst Debjit Chattopadhyay.

Beyond these programs, “we anticipate initiation during 2020 of a Phase 1/2 program of its AbbVie-partnered anti-BCMA TriTAC, HPN217, and its DLL3-targeted, HPN328,” he added.

Mr. Chattopadhyay said the solid tumor microenvironment is likely to present “unique challenges addressable through Harpoon’s modular, redirected T-cell therapy platform alone or potentially in synergistic or additive combination with existing therapeutic modalities.”

As a result, he said readouts from HPN424 and HPN536 are expected to be “meaningful drivers of the stock,” which is trading below its 2019 IPO of $14 and at a multiple to cash of two times.

In addition, Mr. Chattopadhyay said with its most recent downturn, investors appear to have “discounted the $100-million in near-term payments and about $2-billion in potential biobucks from AbbVie.”

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.